The presence of resistance genes as well the classification in phylogenetic groups (A, B1, B2, or D) were performed by PCR ( Table 1 ).
The highest levels of resistance were observed for cefotaxime, ciprofloxacin, and nalidixic acid. Other studies in urinary human E. coli isolates showed lower values. 5 We demonstrated that the CTX-M group of b-lactamases was the predominant ESBL type identified in our isolates, with the bla CTX-M-15 being the most frequent bla gene detected. In Portugal, only dispersed cases of detection of bla CTX-M-15 have been reported. 6 The bla TEM gene was detected in 73.8% of the isolates, bla SHV in 1.5%, bla OXA in 16.9% and bla CTX-M in 89.2% of the 65 E coli isolates. The aac(3)-II gene was detected in 97.4% of the gentamycin-resistant isolates; 51.3% of the streptomycin-resistant isolates presented the aadA gene; the tet(A) and/or tet(B) genes were presented in 45.3% and 37.5% of the tetracyclin-resistant isolates, respectively; the cmlA gene was detected in 54.5% of the chloranphenicol-resistant isolates; and sul1, sul2, and/or sul3 were detected in 40%, 37.5%, and 37.5% of the sulfamethoxazol/trimethoprimresistant isolates, respectively.
It is important to note that the majority of isolates belonged to B2 (63.1%) and D (26.1%) phylogroups and almost all were multi-resistant. The expression of CTX-Mtype b-lactamases may explain this fact. 6 The class 1 integron was present in 35.3% of the sulfamethoxazol/trimetoprim-resistant isolates. The variable region of the class 1 integron was detected in 12 isolates, containing the dfrA15 and aadA1 genes (seven isolates) or the dfrA17, dfrA2þ and aadA5 genes (five isolates). These genes were previously detected in E. coli isolated from human urine samples, conferring resistance to sulfamethoxazol/trimethoprim and streptomycin, respectively. 
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previously been reported as the most frequent on the gyrA gene, in E. coli isolates of human origin. 3 The parC gene was detected in the isolates that were simultaneously resistant to nalidixic acid and ciprofloxacin, and two nonsilent mutations were detected (S80I and E84V).
In conclusion, our study shows a wide variety of resistance genes and inclusion of resistant genes in integrons, in multiresistant ESBL-producing E. coli isolates, obtained from urinary human samples, in a clinical setting. It is important for clinicians and infection-control practitioners to characterize the different types of resistance quickly to allow efficient reduction of the spread of these bacteria and help to select more appropriate antibiotics. 
